A is

Y is —N(R⁵)R⁶;

X is —N(R⁷);

R¹ is R⁸, —CHR¹¹—N(H)—R⁸, —CHR¹¹—O—R⁸, C₂-C₆ alkynyl, C₂-C₆ hydroxyalkynyl, or —C≡N;

R² is unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl

R³ is —H, or unsubstituted C₁-C₆ alkyl;

R⁴ is a —(CR⁹R¹⁰)_t(aryl) or —(CR⁹R¹⁰)_t(heteroaryl);

R⁵ is —H, C₁-C₈ alkyl, —C(O)(CR⁹R¹⁰)_t)N(R⁷)₂, —(CR⁹R¹⁰)_t(aryl), —(CR⁹R¹⁰)_t(heteroaryl), —(CR⁹R¹⁰)_t(cycloalkyl), or —(CR⁹R¹⁰)_t(heterocyclyl);

R⁶ and R⁷ are independently selected from —H, C₁-C₈ alkyl, —(C₁-C₆ alkyl)aryl, or —C(O)(C₁-C₆ alkyl),

R⁵ and R⁶, together with the nitrogen atom to which they are linked, join to form a 5 to 6-membered heterocyclic or heteroaryl ring;

R⁸ is —H, C₁-C₆ alkyl, —(C₁-C₆ alkyl)aryl, aryl, or heteroaryl; and

R⁹, R¹⁰, and R¹¹ are independently selected from —H, C₁-C₆ alkyl, or aryl;

wherein n is 1; m is 1; and t is 1;

wherein each of the above alkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl moieties and heterocyclic and carbocyclic rings are optionally and independently substituted by 1-3 substituents selected from

amino,

aryl, heteroaryl, cycloalkyl, or heterocyclyl optionally substituted by 1-5 substituents selected from

C₁-C₆ alkoxy,

C₁-C₆ alkyl optionally substituted by halo,

aryl,

halo,

hydroxyl,

heteroaryl,

C₁-C₆ hydroxyalkyl, or

—NHS(O)₂—(C₁-C₆ alkyl);

C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ alkoxy, C₁-C₆ alkylamino, C₂-C₆ alkenyl, or C₂-C₆ alkynyl, wherein each of which may be interrupted by one or more hetero

atoms,

cyano,

halo,

hydroxyl,

nitro, or

—O-aryl;

or a pharmaceutically acceptable salt, or stereoisomer thereof.